EGb761 provides a protective effect against Aβ1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Wan, Wen Bin ^a   Cao, Lan ^a   Liu, Lu Mei ^b   Kalionis, Bill ^c   Chen, Chuan ^d   Tai, Xian Tao ^e   Li, Ya Ming ^b   Xia, Shijin ^a  

^a FUDAN UNIVERSITY   (China)

^b HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Shanghai Geriatric Institute of Chinese Medicine   (China)

^e YUNNAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[1-42]; CLAUDIN 5; GINKGO BILOBA EXTRACT; OCCLUDIN; PROTEIN ZO1; REACTIVE OXYGEN METABOLITE; SCAFFOLD PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CLDN5 PROTEIN, HUMAN; GINKGO BILOBA EXTRACT 761; IMMUNOGLOBULIN RECEPTOR; NOOTROPIC AGENT; OCLN PROTEIN, HUMAN; PEPTIDE FRAGMENT; PLANT EXTRACT; TJP1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL CELL; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DRUG EFFECT; ENDOTHELIUM; ENDOTHELIUM CELL; IMMORTALIZED CELL LINE; IN VITRO STUDY; MONOLAYER CULTURE; MOUSE; NONHUMAN; RECEPTOR UPREGULATION; TIGHT JUNCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; TRANSFORMED CELL LINE;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AMYLOID BETA-PEPTIDES; APOPTOSIS; BLOOD-BRAIN BARRIER; CELL LINE, TRANSFORMED; CLAUDIN-5; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; MODELS, BIOLOGICAL; NOOTROPIC AGENTS; OCCLUDIN; PEPTIDE FRAGMENTS; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; TIGHT JUNCTIONS; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84913553690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113126     Document Type: Article

References (42)

1. Muller WE, Heiser J, Leuner K (2012) Effects of the standardized Ginkgo biloba extract EGb 761(R) on neuroplasticity. Int Psychogeriatr 24 Suppl 1: S21-24.
2. Zhang C, Ren C, Chen H, Geng R, Fan H, et al. (2013) The analog of Ginkgo biloba extract 761 is a protective factor of cognitive impairment induced by chronic fluorosis. Biol Trace Elem Res 153: 229-236.
3. Kehr J, Yoshitake S, Ijiri S, Koch E, Noldner M, et al. (2012) Ginkgo biloba leaf extract (EGb 761(R)) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761(R). Int Psychogeriatr 24 Suppl 1: S25-34.
4. Jahanshahi M, Nikmahzar E, Yadollahi N, Ramazani K (2012) Protective effects of Ginkgo biloba extract (EGB 761) on astrocytes of rat hippocampus after exposure with scopolamine. Anat Cell Biol 45: 92-96.
5. Mashayekh A, Pham DL, Yousem DM, Dizon M, Barker PB, et al. (2011) Effects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: a pilot study. Neuroradiology 53: 185-191.
6. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN (2010) Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 10: 14.
7. Evans JR (2013) Ginkgo biloba extract for age-related macular degeneration. Cochrane Database Syst Rev 1: CD001775.
8. Chen Y, Wang C, Hu M, Pan J, Chen J, et al. (2012) Effects of ginkgolide A on okadaic acid-induced tau hyperphosphorylation and the PI3K-Akt signaling pathway in N2a cells. Planta Med 78: 1337-1341.
9. Perrone L, Sbai O, Nawroth PP, Bierhaus A (2012) The Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction. Int J Alzheimers Dis 2012: 734956.
10. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, et al. (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451: 720-724.
11. Pomara N, Sidtis JJ (2010) Alzheimer's disease. N Engl J Med 362: 1844; author reply 1844-1845.
12. Xiao Q, Wang C, Li J, Hou Q, Li J, et al. (2010) Ginkgolide B protects hippocampal neurons from apoptosis induced by beta-amyloid 25-35 partly via up-regulation of brain-derived neurotrophic factor. Eur J Pharmacol 647: 48-54.
13. Love S, Miners S, Palmer J, Chalmers K, Kehoe P (2009) Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front Biosci (Landmark Ed) 14: 4778-4792.
14. Marco S, Skaper SD (2006) Amyloid beta-peptide 1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 401: 219-224.
15. Biron KE, Dickstein DL, Gopaul R, Jefferies WA (2011) Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One 6: e23789.
16. Wan W, Chen H, Li Y (2014) The potential mechanisms of Abeta-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease. Int J Neurosci 124: 75-81.
17. Kook SY, Seok Hong H, Moon M, Mook-Jung I (2013) Disruption of bloodbrain barrier in Alzheimer disease pathogenesis. Tissue Barriers 1: e23993.
18. Choi BR, Cho WH, Kim J, Lee HJ, Chung C, et al. (2014) Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease. Exp Mol Med 46: e75.
19. RJ D (2012) Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem 4: 915-925.
20. Kook SY, Hong HS, Moon M, Ha CM, Chang S, et al. (2012) Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+ )-calcineurin signaling. J Neurosci 32: 8845-8854.
21. Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, et al. (2010) Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J Neuropathol Exp Neurol 69: 98-108.
22. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913.
23. Yan FL, Zheng Y, Zhao FD (2008) Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia. Acta Neuropathol 116: 529-535.
24. Li B, Zhong L, Yang X, Andersson T, Huang M, et al. (2011) WNT5A signaling contributes to Abeta-induced neuroinflammation and neurotoxicity. PLoS One 6: e22920.
25. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, et al. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277: 32046-32053.
26. Kis B, Deli MA, Kobayashi H, Abraham CS, Yanagita T, et al. (2001) Adrenomedullin regulates blood-brain barrier functions in vitro. Neuroreport 12: 4139-4142.
27. Nakagawa S, Deli MA, Nakao S, Honda M, Hayashi K, et al. (2007) Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol 27: 687-694.
28. Zehendner CM, Librizzi L, Hedrich J, Bauer NM, Angamo EA, et al. (2013) Moderate hypoxia followed by reoxygenation results in blood-brain barrier breakdown via oxidative stress-dependent tight-junction protein disruption. PLoS One 8: e82823.
29. Zhou T, He Q, Tong Y, Zhan R, Xu F, et al. (2014) Phospholipid transfer protein (PLTP) deficiency impaired blood-brain barrier integrity by increasing cerebrovascular oxidative stress. Biochemical and biophysical research communications 445: 352-356.
30. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, et al. (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122: 1377-1392.
31. Paul J, Strickland S, Melchor JP (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204: 1999-2008.
32. Chen X, Threlkeld SW, Cummings EE, Juan I, Makeyev O, et al. (2012) Ischemia-reperfusion impairs blood-brain barrier function and alters tight junction protein expression in the ovine fetus. Neuroscience 226: 89-100.
33. Carrano A, Hoozemans JJ, van der Vies SM, Rozemuller AJ, van Horssen J, et al. (2011) Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15: 1167-1178.
34. Gonzalez-Mariscal L, Quiros M, Diaz-Coranguez M (2011) ZO proteins and redox-dependent processes. Antioxid Redox Signal 15: 1235-1253.
35. Bednarczyk J, Lukasiuk K (2011) Tight junctions in neurological diseases. Acta Neurobiol Exp (Wars) 71: 393-408.
36. Liu WY, Wang ZB, Zhang LC, Wei X, Li L (2012) Tight junction in bloodbrain barrier: an overview of structure, regulation, and regulator substances. CNS Neurosci Ther 18: 609-615.
37. Slowik A, Merres J, Elfgen A, Jansen S, Mohr F, et al. (2012) Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)-and amyloid beta1-42-induced signal transduction in glial cells. Mol Neurodegener 7: 55.
38. Ramasamy R, Yan SF, Schmidt AM (2012) Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 42: 1151-1161.
39. Han SH, Kim YH, Mook-Jung I (2011) RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 31: 91-97.
40. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8: 16-30.
41. Yan SD, Roher A, Chaney M, Zlokovic B, Schmidt AM, et al. (2000) Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid betapeptide. Biochim Biophys Acta 1502: 145-157.
42. Deane R, Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4: 191-197.